Bronchospasm News and Research

RSS

Rising incidence of kiwifruit allergy in children: study highlights severe allergic reactions

Study aimed to compile Kiwifruit allergy recognition patterns to enhance patient management and clinical practice.

6 Jul 2023

From delicacy to danger: The rising tide of shellfish allergies in children revealed

Shellfish consumption is on the rise, but so are shellfish allergies, particularly among children. A recent review delves into the epidemiology, symptoms, diagnosis, and management of shellfish allergies, highlighting the need for improved diagnostic tools and potential allergen immunotherapy.

13 Jun 2023

Hospital financial decisions play a role in the critical shortage of pediatric beds for RSV patients

The dire shortage of pediatric hospital beds plaguing the nation this fall is a byproduct of financial decisions made by hospitals over the past decade, as they shuttered children's wards, which often operate in the red, and expanded the number of beds available for more profitable endeavors like joint replacements and cancer care.

9 Dec 2022

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

Childhood asthma is not a risk factor for COVID-19

A new study provides new insights on the association of childhood asthma and COVID-19.

26 Sep 2021

Commentary on severe allergic reaction to mRNA SARS-CoV-2 vaccines

A commentary by John M. Kelso, Division of Allergy, Asthma and Immunology, Scripps Clinic, published in the latest issue of the journal Vaccines, discusses anaphylactic reactions to these novel mRNA SARS-CoV-2/COVID-19 vaccines.

8 Feb 2021

Tocilizumab in Critical COVID-19 Patients

A new study by scientists at Metro Infectious Disease Consultants and published on the preprint server medRxiv* in June 2020 reports that the cytokine blocker tocilizumab is a useful adjunct to supportive medical care in severe COVID-19, with increased survival and a lower requirement for mechanical ventilation.

10 Jun 2020

Spraying disinfectants on streets can be harmful, WHO warns

The interim guidance released by the WHO aims to help health authorities formulate and implement policies on the disinfection of environmental surfaces during the coronavirus disease (COVID-19) pandemic.

18 May 2020

Dopamine may worsen lung inflammation in asthma

A new study on a mouse model of asthma shows that nerve cells producing dopamine, a neurotransmitter, signal T cells in the body to promote inflammation due to allergic reactions in the lungs during childhood but not in adult mice.

19 Nov 2019

Study uncovers cause of asthmatic lung spasms

Researchers at Rutgers and other institutions have discovered how muscle contraction (bronchospasm) in the airway, which cause breathing difficulty in people with asthma, occur by creating a microdevice that mimics the behavior of the human airways.

22 Aug 2019

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

As one of the most common malignant tumors, gastric cancer occupies the second leading cause of cancer-related deaths worldwide with an increasing trend.

18 Sep 2018

FDA recalls montelukast tablets by Camber Pharmaceuticals due to drug mix-up

The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.

3 Sep 2018

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

14 Nov 2017

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix, Inc., today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a currently marketed once daily bronchodilator, formulated in the company's proprietary iSPERSETM dry powder delivery technology.

22 Jul 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

17 Dec 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015